Sionna Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Sionna Therapeutics Inc 's ROA in the second quarter of 2026?
Sionna Therapeutics Inc recorded a cumulative net loss of $-97 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -31.08%.

However, within the Healthcare sector 431 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3560, from total ROA ranking in the first quarter of 2026 at 4097.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-19.54 %	-17.48 %	587.03 %	-	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-97	-86	-75	-71	-76
Return On Assets (TTM)	-31.08 %	-25.88 %	-21.71 %	-25.5 %	-39.44 %
SION's Total Ranking	# 3560	# 4097	#	#	#
Total Assets (TTM) in million	283	305	326	339	352
Seq. Total Assets Change	-7.14 %	-6.42 %	-3.93 %	-3.63 %	-4.77 %
Seq. Net Income Change	-	-	-	-	-

SION's 5 Years Annual ROA >> Back to SION Management Effectiveness >> Compare SION ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 167
Sector	# 432
Overall	# 3625

Return On Assets Statistics
High	Average	Low
-21.71 %	-26.22 %	-31.08 %
(Dec 31 2025)		(Jun 30 2026)

News about Sionna Therapeutics Inc Return on Assets ROA

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data o...

Advanced Insights from Sionna Therapeutics: Promising Phase 1 Data Revealed at the 2025 North American Cystic Fibrosis ConferenceAt the recent 2025 North American Cystic Fibrosis Conference, Sionna Therapeutics made significant waves within the medical and scientific communities by unveiling key findings from their Phase 1 trials of two novel compounds: SION-719 and SION-451. These first-in-class NBD1 stabilizers are being developed to address the underlying causes of cystic fibrosis, a debilitating genetic disorder characterized by the malfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The presented data indicated that both SION-719 and SION-451 were generally well tolerated among participants, showcasing a favorable safety profile that is crucial for any therapeutic candidate. Importantly, these compounds exceeded the predefined pharmacokinetic targets, reinforcing their viability as potential treatment options for patients with cystic fibrosis, particularly those carrying the F508del mutation a mutation most commonly associated with the disease.In addition to the data from the Phase 1 studies, Sionna Therapeutics also presented new preclinical findings on the impact of NBD1 stabilizers on the half-life of F508del-CFTR. This innovative approach involves the stabilization of the Nucleotide Binding Domain 1 (NBD1) of CFTR, which is often misfolded in individuals with cystic fibrosis. By enhancing the stability of the CFTR protein, Sionna Therapeutics aims not only to improve protein folding but also to extend its functional lifespan on the cell surface, thereby enhancing chloride ion transport and alleviating the symptoms of the disease.

Financial Statements
Sionna Therapeutics Inc 's Assets	$ 283 million	SION's Balance sheet
Sionna Therapeutics Inc 's Income	$ -30 million	Quarterly SION's Income Statement
SION's Income by Division		See SION's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	FY	FY	FY	FY
Y / Y Total Assets Change	-	-	-	-	-
Total Assets in million	244	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-75	0	0	0	0
Annual Return On Assets	-30.89 %	-	-	-	-

SION's 5 Years Annual ROA >> Back to SION Management Effectiveness >> Compare SION ROA to its Competitors

More Return On Assets Ratios
SION's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SION's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SION's Competitors
Subscribers only: Roa for Sionna Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for SION's Customers

You may also want to know
SION's Roi	SION's Inventory Turnover Ratio	SION's Growth Rates	SION's Dividend Comparisons
	SION's Profitability Ratios	SION's Asset Turnover Ratio	SION's Dividend Growth
SION's Roe	SION's Valuation Ratios	SION's Financial Strength Ratios	SION's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T22:16:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.